ArticleJournal of managed care & specialty pharmacy2021
Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Estimating the Impact of Hemophilia A Treatment Administration on Patient Health Utility: Combining a Discrete Choice Experiment with Time Trade-Off Method.Advances in therapy · 2026Article
- Evaluating Costs and Efficacy of rFVIII Prophylaxis Using Matching-Adjusted Indirect Comparisons in Hemophilia A.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Article
- Clinical Burden and Healthcare Resource Use Among Adults Living with Hemophilia A: An Observational Study.Drugs - real world outcomes · 2025Article
- Public health assistance for people with haemophilia in Brazil (PATCH study): a cross-sectional study protocol.BMJ open · 2025Article
- A Global Cross-Sectional Database Study of Low Dose FVIII SHL Prophylaxis in Haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- Burden of Haemophilia A in South Korea: A Serial Cross-Sectional Study From 2008 to 2021.Haemophilia : the official journal of the World Federation of Hemophilia · 2025Article
- Distribution and predictors of haemophilia-related costs in the United Kingdom: analysis of the CHESS I and CHESS II burden of illness studies.BMC health services research · 2024Article
- Assessing health care resource use, outcomes, and costs among Medicaid beneficiaries receiving factor IX prophylaxis for hemophilia B.Journal of managed care & specialty pharmacy · 2024Article
- Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia.Journal of racial and ethnic health disparities · 2024Article
- Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid.PharmacoEconomics · 2024Article
- Health care costs and resource use of managing hemophilia A: A targeted literature review.Journal of managed care & specialty pharmacy · 2023Article
- Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A.Haemophilia : the official journal of the World Federation of Hemophilia · 2023Article
- Resource utilization and treatment costs of patients with severe hemophilia A: Real-world data from the ATHNdataset.EJHaem · 2022Article
- Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.Journal of managed care & specialty pharmacy · 2022Article
- Health insurance coverage and switching among people with hemophilia A in the United States.Journal of managed care & specialty pharmacy · 2022Article
- Effectiveness of Prophylactic Coagulation Factor Replacement Therapy in Patients with Severe Hemophilia A in Taiwan - A Population-Based Study.Clinical epidemiology · 2022Article
- Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies.Journal of managed care & specialty pharmacy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.